• 목록
• 게시판 리스트 옵션
  • 수정
  • 삭제

Ment. Am J Pathol 1998, 152(5):1327-1336. 113. Czermak BJ, Lentsch AB, Bless NM, Schmal H, Friedl HP, Ward PA: Role of complement in in vitro and in vivo lung inflammatory reactions. J Leukoc Biol 1998, 64(1):40-48. 114. Drouin SM, Kildsgaard J, Haviland J, Zabner J, Jia HP, McCray PB Jr, Tack BF, Wetsel RA: Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma. J Immunol 2001, 166(3):2025-2032.Neher et al. Journal of Biomedical Science 2011, 18:90 http://www.jbiomedsci.com/content/18/1/Page 14 of115. Riedemann NC, Guo RF, Sarma VJ, Laudes IJ, Huber-Lang M, Warner RL, Albrecht EA, Speyer CL, Ward PA: Expression and function of the C5a receptor in rat alveolar epithelial cells. J Immunol 2002, 168(4):1919-1925. 116. Bozic CR, Lu PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/21715270 B, Hopken UE, Gerard C, Gerard NP: Neurogenic amplification of immune complex inflammation. Science 1996, 273(5282):1722-1725. 117. Heller T, Hennecke M, Baumann U, 2,2,3,3-Tetrafluoropropyl N,N'-diethylcarbamimidothioate trifluoromethanesulfonate Gessner JE, zu Vilsendorf AM, Baensch M, Boulay F, Kola A, Klos A, Bautsch W, et al: Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury. J Immunol 1999, 163(2):985-994. 118. Shushakova N, Skokowa J, Schulman J, Baumann U, Zwirner J, Schmidt RE, Gessner JE: C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J Clin Invest 2002, 110(12):1823-1830. 119. Ohno M, Hirata T, Enomoto M, Araki T, Ishimaru H, Takahashi TA: A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/3081428 mature dendritic cells. Ethyl (4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbamate hydrochloride Mol Immunol 2000, 37(8):407-412. 120. Cain SA, Monk PN: The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74). J Biol Chem 2002, 277(9):7165-7169. 121. Gerard NP, Lu B, Liu P, Craig S, Fujiwara Y, Okinaga S, Gerard C: An antiinflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. J Biol Chem 2005, 280(48):39677-39680. 122. Guo RF, Lentsch AB, Sarma JV, Sun L, Riedemann NC, McClintock SD, McGuire SR, Van Rooijen N, Ward PA: Activator protein-1 activation in acute lung injury. Am J Pathol 2002, 161(1):275-282. 123. Gao H, Guo RF, Speyer CL, Reuben J, Neff TA, Hoesel LM, Riedemann NC, McClintock SD, Sarma JV, Van Rooijen N, et al: Stat3 activation in acute lung injury. J Immunol 2004, 172(12):7703-7712. 124. Tang H, Yan C, Cao J, Sarma JV, Haura EB, Wu M, Gao H: An essential role for Stat3 in regulating IgG immune complex-induced pulmonary inflammation. FASEB J 2011. 125. Ware LB, Matthay MA: The acute respiratory distress syndrome. N Engl J Med 2000, 342(18):1334-1349. 126. Hammerschmidt DE, Weaver LJ, Hudson LD, Craddock PR, Jacob HS: Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome. Pathophysiological relevance and possible prognostic value. Lancet 1980, 1(8175):947-949. 127. Weigelt JA, Chenoweth DE, Borman KR, Norcross JF: Complement and the severity of pulmonary failure. J Trauma 1988, 28(7):1013-1019. 128. Proctor LM, Strachan AJ, Woodruff TM, Mahadevan IB, Williams HM, Shiels IA, Taylor SM: Complement inhibitors selectively attenuate injury following administration of cobra venom factor to rats. Int Immunopharmacol 2006, 6(8):1224-1232. 129. Moore FA, Moore EE: Evolving concepts in the pathogenesis of postinjury mult.